WALTHAM, Mass.--(BUSINESS WIRE)--X-Chem, the pioneer of DNA-encoded library (DEL) technology and artificial intelligence (AI) for small molecule drug discovery, today announced that Senior Vice President and General Manager Noor Shaker was named a winner in the Artificial Intelligence Excellence Awards program from Business Intelligence Group. Shaker is one of six receiving an individual award, which recognizes people, organizations and products bringing AI to life and applying it to solve real problems.
“I am very passionate about data and pushing the boundaries for what is possible with AI,” Shaker said. “AI is set to transform nearly every aspect of our lives and culture, and its use to increase the efficiency of drug discovery has increased considerably over the past few years. The ultimate aim of our team at X-Chem is to cure disease — and we believe that our AI technology, combined with our DEL and medicinal chemistry expertise, will help enable this step change in drug discovery.”
Shaker has a record of achievements in AI, including numerous patents and papers published in the field and its application to drug discovery and AI. She also sits on AI and diversity advisory boards for several prestigious organizations and universities.
“We are so proud to name Noor Shaker as a winner in our inaugural Artificial Intelligence Excellence Awards program,” said Maria Jimenez, chief nominations officer for Business Intelligence Group. “It was clear to our judges that Noor was using AI to improve the lives of their customers and employees. Congratulations to the entire team!”
X-Chem is a leader in small molecule drug discovery services for pharmaceutical and biotech companies. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. As experts in medicinal chemistry, X-Chem can take those leads and progress them to clinical candidates with unmatched speed. Throughout the process, X-Chem’s advanced proprietary artificial intelligence (AI) technology accelerates all steps in the process. X-Chem also provides libraries, reagents and informatic tools to allow DEL operators to get the most of their DEL platform. X-Chem empowers its partners to effectively build drug pipelines from target to clinical candidate, enhanced with AI. For further information, please visit www.x-chemrx.com.